Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹400Cr
Rev Gr TTM
Revenue Growth TTM
10.87%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

RUBFILA
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | -14.2 | -5.9 | 2.2 | 2.8 | 13.4 | 5.4 | 17.5 | 34.0 | 14.7 | 11.3 | 11.5 | 6.3 |
| 104 | 115 | 104 | 97 | 118 | 119 | 125 | 126 | 135 | 135 | 139 | 138 |
Operating Profit Operating ProfitCr |
| 8.6 | 7.1 | 9.2 | 5.5 | 8.7 | 8.4 | 6.9 | 8.6 | 8.5 | 6.8 | 7.3 | 5.9 |
Other Income Other IncomeCr | 1 | 4 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 2 | 2 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 9 | 10 | 9 | 4 | 10 | 10 | 8 | 11 | 11 | 9 | 11 | 7 |
| 3 | 2 | 2 | 1 | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 2 |
|
Growth YoY PAT Growth YoY% | -44.1 | -32.0 | 10.3 | 86.8 | 20.4 | -10.5 | -19.7 | 182.3 | 17.2 | -6.2 | 32.5 | -30.9 |
| 5.2 | 6.5 | 6.6 | 2.7 | 5.5 | 5.5 | 4.5 | 5.8 | 5.6 | 4.6 | 5.3 | 3.8 |
| 1.1 | 1.5 | 1.4 | 0.5 | 1.2 | 1.3 | 1.1 | 1.5 | 1.6 | 1.2 | 1.5 | 1.0 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | -0.5 | 20.7 | 25.2 | 47.6 | -4.1 | 2.8 | 17.2 | 7.1 |
| 183 | 190 | 234 | 274 | 412 | 420 | 434 | 506 | 547 |
Operating Profit Operating ProfitCr |
| 14.9 | 11.3 | 9.2 | 15.2 | 13.6 | 8.2 | 7.7 | 8.1 | 7.1 |
Other Income Other IncomeCr | 4 | 3 | 5 | 3 | 3 | 7 | 8 | 6 | 7 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 4 | 3 | 6 | 6 | 7 | 9 | 11 | 11 | 11 |
| 33 | 24 | 22 | 45 | 60 | 35 | 33 | 40 | 38 |
| 11 | 6 | 6 | 12 | 16 | 9 | 7 | 10 | 10 |
|
| | -16.0 | -4.7 | 98.1 | 33.5 | -41.9 | -2.1 | 15.9 | -3.2 |
| 9.8 | 8.3 | 6.5 | 10.3 | 9.4 | 5.7 | 5.4 | 5.3 | 4.8 |
| 4.8 | 3.7 | 3.3 | 6.4 | 8.3 | 4.8 | 4.6 | 5.5 | 5.3 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Dec 2025 |
|---|
Equity Capital Equity CapitalCr | 23 | 24 | 25 | 27 | 27 | 27 | 27 | 27 | 27 |
| 89 | 109 | 128 | 170 | 208 | 225 | 243 | 267 | 276 |
Current Liabilities Current LiabilitiesCr | 16 | 15 | 38 | 40 | 37 | 33 | 31 | 36 | 31 |
Non Current Liabilities Non Current LiabilitiesCr | 10 | 10 | 16 | 19 | 22 | 26 | 29 | 29 | 30 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 77 | 64 | 78 | 110 | 127 | 123 | 151 | 184 | 188 |
Non Current Assets Non Current AssetsCr | 63 | 94 | 131 | 145 | 167 | 188 | 179 | 174 | 176 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 4 | 37 | 37 | 14 | 35 | 30 | 28 | 25 |
Investing Cash Flow Investing Cash FlowCr | -11 | -39 | -43 | -20 | -26 | -24 | -1 | -7 |
Financing Cash Flow Financing Cash FlowCr | 8 | 2 | 6 | 10 | -7 | -10 | -7 | -7 |
|
Free Cash Flow Free Cash FlowCr | -11 | 11 | 6 | -8 | 5 | 4 | 27 | 19 |
| 20.3 | 207.5 | 218.9 | 42.8 | 78.2 | 117.1 | 109.9 | 86.3 |
CFO To EBITDA CFO To EBITDA% | 13.3 | 152.6 | 155.9 | 29.2 | 53.8 | 81.3 | 77.6 | 56.8 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 325 | 195 | 116 | 323 | 500 | 335 | 370 | 345 |
Price To Earnings Price To Earnings | 15.4 | 11.0 | 6.9 | 9.7 | 11.2 | 12.9 | 14.6 | 11.7 |
Price To Sales Price To Sales | 1.5 | 0.9 | 0.5 | 1.0 | 1.1 | 0.7 | 0.8 | 0.6 |
Price To Book Price To Book | 2.9 | 1.5 | 0.8 | 1.6 | 2.1 | 1.3 | 1.4 | 1.2 |
| 10.0 | 8.0 | 4.7 | 6.4 | 7.5 | 8.8 | 9.5 | 6.7 |
Profitability Ratios Profitability Ratios |
| 29.7 | 27.5 | 27.9 | 34.5 | 30.2 | 29.1 | 27.8 | 26.6 |
| 14.9 | 11.3 | 9.2 | 15.2 | 13.6 | 8.2 | 7.7 | 8.1 |
| 9.8 | 8.3 | 6.5 | 10.3 | 9.4 | 5.7 | 5.4 | 5.3 |
| 29.3 | 18.0 | 14.8 | 22.9 | 25.6 | 14.0 | 12.1 | 13.5 |
| 18.9 | 13.3 | 11.1 | 16.9 | 19.0 | 10.3 | 9.4 | 10.0 |
| 15.1 | 11.2 | 8.1 | 13.1 | 15.2 | 8.3 | 7.7 | 8.2 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Rubfila International Ltd (RIL) is the holding company of a diversified manufacturing group with core operations in two distinct yet strategically aligned consumer and industrial segments:
1. **Latex rubber thread manufacturing** under the flagship **Rubfil** brand (Rubfila International Ltd).
2. **Tissue and hygiene products** through its wholly-owned subsidiary, **Premier Tissues India Ltd (PTIL)**, which also operates in the **home care product** segment.
RIL has built a strong reputation over decades, with the **Rubfil brand established for nearly 40 years**, initially through Malaysian origins and later strengthened under RIL’s ownership since 1995. The company maintains leadership positions in both domestic and international markets and is actively pursuing growth through geographic expansion, capacity enhancement, and operational optimization.
---
### **Core Business Segments**
#### **1. Rubfila International Ltd – Rubber Thread Manufacturing**
- **Primary Segment**: Manufacture and sale of heat-resistant **latex rubber thread**, a critical raw material for the **innerwear and garment industries**.
- **Market Position**: **Market leader in India** with the **largest manufacturing capacity** of 20,000 metric tons per annum (expanded via new production lines commissioned in 2020 and 2021).
- **Revenue Mix (as of FY22)**:
- Domestic (India): ₹3,294.17 crores
- Export (Asia, America, Europe, Africa): ₹854.99 crores (~21% of total sales)
- **Export target**: 25% of total sales (targeted as of 2020, on track).
#### **2. Premier Tissues India Ltd – Tissue & Hygiene Products**
- **Primary Segment**: Manufacture and sale of **tissue paper**, **hygiene products**, and **home care items** (e.g., dish wash liquid, toilet cleaner, detergent).
- **Brands**: Premier (premium), Royal (value segment).
- **Market Position**: Recognized as one of India’s **most respected tissue brands**, with strong brand equity and a growing national footprint.
- **Growth**: Tissue sales grew **44% YoY** in FY23, driven by post-pandemic hygiene demand and product diversification.
---
### **Strategic Highlights (2022–2025)**
#### **Capacity Expansion & Operational Scale**
- **Rubfila**:
- **300% increase in production capacity** since 2017; total capacity now at **20,000 MT/year**.
- New production line in Udumalpet, Tamil Nadu, commissioned in 2020 despite pandemic disruptions.
- Expansion of Tamil Nadu plant planned to capture greater share of **global rubber thread market**.
- **Premier Tissues**:
- **Asset-light model** adopted to reduce logistical costs.
- Establishment of **offsite satellite conversion centers** near high-potential markets:
- **West Bengal (Eastern India)** – Operational.
- **Western India (near Mumbai)** – Planned.
#### **Geographic & Market Expansion**
- **Rubfila**:
- Aims to expand into **untapped global markets**, leveraging the **strong international brand equity** of 'Rubfil'.
- Focus on **Americas** as a new growth frontier; customer development and sampling in progress.
- **Export growth trajectory** is upward, supported by increased capacity and new customer acquisitions.
- **Premier Tissues**:
- Historically strong in **South and West India**; actively expanding in **North and East India**.
- **Weak sales infrastructure** and **high logistics costs** from Mysore plant being addressed via **regional conversion units** and **expansion of distributor network**.
- Building robust **sales teams** in underpenetrated regions to improve national market presence.
#### **Brand & Product Development**
- **Rubfil Brand**:
- Over **40 years of brand equity**, trusted in global markets.
- Serves major hosiery clusters across India (Delhi, Kolkata, Surat, Tirupur, Ahmedabad).
- Known for **reliability, quality, and long-standing customer loyalty**, especially in Europe.
- **Premier Tissues**:
- Launched **new hygiene products** (sanitizing wipes, disinfectant sprays) in 2020–21 to meet pandemic-driven demand.
- Expanded into **home care segment** with soft launch in Kerala (2022), now scaling nationally.
- **Packaging redesign** and **new product variants** have been well-received.
---
### **Key Strengths**
1. **Dual-Market Leadership**:
- Dominant in domestic rubber thread market; respected player in organized tissue segment.
2. **Resilient Demand**:
- Core end-use industries (innerwear, hygiene) are **relatively recession-resistant**.
3. **Strong Brand Equity**:
- Both **Rubfil** (industrial) and **Premier** (consumer) enjoy high reputation and trust.
4. **Strategic Asset Utilization**:
- 11.87 acres of **freehold land in Pollachi** (valued at ₹128.15 million) classified as investment property.
- **Leasing manufacturing space** to subsidiary (Premier) for internal efficiency (since 2021).
5. **Long-Term Growth Potential**:
- India’s **per capita tissue consumption** (~250 grams) is far below global average (5.2 kg), signaling **huge untapped market**.
- Rising income, urbanization, and hygiene awareness support sustained growth.
---
### **Challenges & Risks**
#### **Raw Material & Cost Pressures**
- **High domestic latex prices** in India due to:
- Unfavorable government import policies.
- Climate-related fluctuations affecting rubber tapping.
- Restricted latex imports and inverted duty structures.
- **Disparity** with lower international latex prices (e.g., Malaysia, Thailand) threatens **cost competitiveness**.
#### **Competitive Threats**
- **Low-cost imports** from **Malaysia and Thailand** (benefiting from **free trade agreements**) create pricing pressure.
- **Chinese exporters** dumping excess rubber thread stock.
- **Spandex substitution**: Growing use of synthetic **spandex** in elastic tapes and garments poses **long-term threat** to rubber thread demand.
#### **Operational & Market Challenges**
- **Manpower shortages** in regional markets hindering distribution expansion (as of Aug 2025).
- RIL exploring **gig-sector labor models** as alternative solution.
- **Domestic market fragmentation**: Organized tissue players face competition from **low-cost unorganized sector**.
- **Potential price wars** due to industry-wide **capacity overhang** and new entrants.
#### **Supply Chain Risks**
- **Volatility in natural rubber supply** due to rubber growers in **Kerala shifting to alternative crops** (due to non-remunerative prices).
- **Long-term raw material security** at risk if rubber cultivation continues to decline.